TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CP-690,550 and Midazolam Drug-Drug Interaction Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and/or female (non-child bearing potential) subjects~Exclusion Criteria:~* Clinically significant infections within the past 3 months~* History of previously untreated infection with Mycobacterium tuberculosis~* Positive screening test for hepatitis B surface antigen, anti-hepatitis C antibody, or human immunodeficiency virus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Treatment Sequence 1 (Type: EXPERIMENTAL): None
- Treatment Sequence 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telmisartan in Haemodialysis Patients With Chronic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult haemodialysis patients with CHF;~* New York Heart Association (NYHA) class II and III;~* Ejection fraction less or equal to 40% determined within 6 months; and~* Therapy with ACE inhibitors individually optimized and unchanged for 30 days before randomization~Exclusion Criteria:~* Hypotension during dialysis;~* Atrial fibrillation;~* Intolerant to low dose of telmisartan

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* voluntarily~* age \> 18 years old~Exclusion Criteria:~* current use of medication (e.g. analgetics, antiepileptics, antidepressants, etc.)~* prevailing organic disease (e.g. diabetes, vascular or neurologic illness, etc.)~* previous physical trauma of the forearm (e.g. burning, surgery)~* primary organ failure~* pregnancy and lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Placebo first (Type: EXPERIMENTAL): Volunteers receive placebo first and after a cross-over period of at least 7 days flupirtine second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention
- Flupirtine first (Type: EXPERIMENTAL): Volunteers receive flupirtine first and after a cross-over period of at least 7 days placebo second. On the days of the experiment outcome is taken as the change in excitability from Baseline (all measures before intervention) to a timepoint two hours after intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of prostate adenocarcinoma.~* Metastatic prostate cancer progressive on imaging studies and/or rising PSA despite adequate medical or surgical castration therapy.~* Progressed following discontinuation of anti-androgen therapy, if received.~* Serum testosterone \< 50 ng/ml~Exclusion Criteria:~* Use of corticosteroids and/or adrenal hormone inhibitors within 4 weeks of treatment.~* Use of PC-SPES within 4 weeks of treatment.~* Use of red blood cell or platelet transfusions within 4 weeks of treatment.~* Use of hematopoietic growth factors within 4 weeks of treatment.~* Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.~* Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton.~* Prior radiation therapy encompassing \>25% of skeleton.~* Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).~* Active angina pectoris or NY Heart Association Class III-IV.~* History of deep vein thrombophlebitis and/or pulmonary embolus within 3 months of study entry.~* Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.~* Prior monoclonal antibody therapy with the exception of ProstaScint®~* Prior investigational therapy (medications or devices) within 6 weeks of treatment.~* Known history of HIV

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~- Confirmed diagnosis of SJIA as per International League Against Rheumatism (ILAR) definition (Petty, et al. 2004) that must have occurred at least 3 months prior to enrollment with an onset of disease \< 16 years of age: Arthritis in one or more joints, with or preceded by fever of at least 2 weeks duration that is documented to be daily/quotidian for at least 3 days and accompanied by one or more of the following: Rash due to SJIA, lymphadenopathy, Hepatomegaly/Splenomegaly, Serositis~* Active disease at the time of baseline defined as follows:~* At least 2 joints with active arthritis~* Documented spiking, intermittent fever (body temperature \> 38°C) for at least 1 day during the screening epoch and within 1 week before first canakinumab dose~* C-Reactive Protein (CRP) \> 30 mg/L(3 mg/dL) (normal range \< 10 mg/L(1 mg/dL))~* Negative TB screen (Chest X-ray and T-SPOT test)~Exclusion Criteria:~* With active or recurrent bacterial, fungal or viral infection at the time of enrollment, including patients with evidence of Human Immunodeficiency Virus (HIV) infection, Hepatitis B and Hepatitis C infection. Patients with resolved/previous hepatitis B infection (a negative HBs antigen, but a positive anti-HBs antibody and/or anti-HBc antibody).~* With underlying metabolic, renal, hepatic, infectious or gastrointestinal conditions which in the opinion of the investigator immunocompromises the patient and /or places the patient at unacceptable risk for participation.~* With neutropenia (absolute neutrophil count \< 1500/mm3) at screening.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): All patients received canakinumab (ACZ885) as open-label study medication. Patients were administered canakinumab 4 mg/kg every 4 weeks. The maximal total single dose of canakinumab allowed was 300 mg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Completely resected histologically confirmed cutaneous melanoma stage IIIA (LN metastasis \>1 mm), IIIB, IIIC, IIID \[AJCC (ed 8)\] no more than 12 weeks, from last surgery, before Day 1~  1. Subjects presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma were eligible.~ 2. Subjects who had previously had Stage III melanoma at any time were not eligible.~ 3. Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).~* V600E/K mutation positive using a validated local test~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1~Key Exclusion Criteria:~* Uveal or mucosal melanoma~* Evidence of metastatic disease including unresectable in-transit metastasis~* Received any prior adjuvant or neoadjuvant treatment, including but not limited to chemotherapy, checkpoint inhibitors, targeted therapy \[e.g., BRAF and/or MEK inhibitors\], biologic therapy, vaccine therapy, investigational treatment, or radiotherapy for melanoma~* Malignant disease, other than that being treated in this study. Exceptions to this exclusion include the following: malignancies that were treated curatively and had not recurred within 2 years prior to study treatment; completely resected basal cell and squamous cell skin cancers and any completely resected carcinoma in situ~* History or current evidence of cardiovascular risk~* A history or current evidence/risk of retinal vein occlusion (RVO) or central serous retinopathy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dabrafenib and trametinib combination therapy (Type: EXPERIMENTAL): Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for up to 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comprehensive Magnetic Resonance of Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients age 30-85 referred to the vascular imaging laboratory with documented evidence of peripheral arterial disease (0.4\<ABI\<0.9) 96 Normal healthy subjects ages 30-85~Exclusion Criteria:~Age\<30, \>85~GFR less than 45mL/min based on a serum creatinine drawn within 90 days of the MRI:~Pregnancy Contraindications to a magnetic resonance examination~* Intracranial clips~* Implantable pacemaker and defibrillator~* Cochlear or intraocular implants~* Claustrophobia~* Any metallic implant not listed as magnetic resonance compatible in Shellock F.G ---Pocket Guide to Magnetic Resonance Procedures and Metallic Objects, Update 2000. Lippincott, Williams and Wilkins

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Randomized (Type: EXPERIMENTAL): Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
- Ezetemibe (Type: EXPERIMENTAL): Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients at least 18 years of age with histologically confirmed solid tumor carcinomas (except lung) or multiple myeloma~* Radiographic evidence of 1 or more bone lesions or lytic lesion in myeloma~* Currently receiving IV bisphosphonates~* Urinary N-Telopeptide (uNTx) greater than 50 nM BCE/mM creatinine~* Eastern Cooperative Oncology Group (ECOG) 0, 1 or 2~Exclusion Criteria:~* More than 2 prior skeletal related events (SRE)~* Known brain metastases~* Prior history or current evidence of osteonecrosis/osteomyelitis of the jaw~* Active dental or jaw conditions which requires oral surgery~* Non-healed dental/oral surgery~* Prior administration of AMG 162~* Evidence of impending fracture in weight bearing bones~* Pregnancy or breastfeeding. Subjects must be surgically sterile, postmenopausal, or must agree to use effective contraception during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Bisphosphonates q 4 weeks (Type: ACTIVE_COMPARATOR): This is an open-label randomization to receive IV bisphosphonate (administered per package insert) every 4 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will receive AMG 162 180mg (SC) every 4 weeks.
- 180 mg AMG 162 (SC) q 12 weeks (Type: EXPERIMENTAL): This is an open-label randomization to receive 180 mg AMG 162 (SC) every 12 weeks during the treatment phase. If subjects are enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 12 weeks.
- 180 mg AMG 162 (SC) q 4 weeks (Type: EXPERIMENTAL): This is an open-label randomization to receive 180 mg AMG 162 (SC) every 4 weeks during the treatment phase. If subject is enrolled into the extension phase, they will continue to receive 180 mg AMG 162 (SC) every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hyperglycemia in Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients~* diabetic~* end stage renal disease undergoing cadaveric renal transplant~Exclusion Criteria:~* enrolled in concurrent study to test impact of a drug on graft function after transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tight glucose control (Type: EXPERIMENTAL): Patients randomized to the tight glucose control arm will be placed on an insulin infusion, or continuous low dose insulin drip.
- Standard glucose control (Type: ACTIVE_COMPARATOR): Patients randomized to the standard glucose control group will be given subcutaneous doses of insulin every few hours based on their blood sugar.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Longterm HPN With Two Lipid Emulsions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* Age: 18-80 years~* Male and female patients~* Patients with a newly indicated need of long-term home parenteral nutrition (HPN) for at least 8 weeks~* Patients with an insufficient resorption capacity of the colon that may not be compensated by enteral nutrition~* mentally and physically able to adhere to study procedures.~* Females agree to apply adequate contraception~Exclusion Criteria:~* Participation in a clinical study with an investigational drug within one month prior to the start of study~* Patients with sepsis, severe sepsis and septic shock~* Known or suspected drug abuse~* General contra indications for infusion therapy such as acute pulmonary edema, hyperhydration and decompensated cardiac insufficiency~* Pregnancy and lactation~* Autoimmune disease as e.g. HIV~* Known hypersensitivity to egg-, soy-, and fish proteins or any of the ingredients~* Hemodynamic failure of any origin (hemorrhagic shock, myocardial infarction, cardiac failure)~* Alterations of coagulation (thrombocytes \<150.000 mm3), PT \< 50%, PTT \> 40 sec~* Diabetes mellitus with known ketoacidosis within 7 days before onset of study~* Renal insufficiency with serum creatinine \> 1.4 mg/dL(\>124 mmol/L)~* Patients with severe liver dysfunction with bilirubin \>2.5 mg/dL (\> 43 µmol/L)~* Lipid disorders, in particular fasting serum triglycerides \> 250 mg/dL (\>2.86 mmol/L)~* necrotizing pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): treatment with Lipoplus \& Nutriflex plus (commercially available and marketed 2 Chamber Bag)
- 2 (Type: ACTIVE_COMPARATOR): treatment with Lipofundin MCT \& Nutriflex plus (commercially available and marketed 2 Chamber Bag)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Employment-Based Depot Naltrexone Clinical Trial II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Individuals were eligible if they:~* met the Diagnostic and Statistical Manual (DSM)-IV criteria for opioid dependence,~* reported using heroin at least 21 of the last 30 days while living in the community,~* were unemployed,~* were 18-65 years old,~* were medically approved for naltrexone,~* lived in or near Baltimore, MD.~Individuals were excluded if they:~* were pregnant or breastfeeding,~* had serum aminotransferase levels over three times normal,~* had current hallucinations, delusions, or thought disorders, current suicidal or -homicidal ideation,~* expressed interest in methadone treatment,~* were required to use opioids for medical purposes,~* earned over $200 in taxable income over the previous 30 days,~* had physical limitations that would prevent them from using a keyboard, or were incarcerated or under constant monitoring by the criminal justice system.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Work Plus Naltrexone Prescription (Type: NO_INTERVENTION): Participants could work and earn vouchers but did not to take Vivitrol Injections to work and earn vouchers.
- Work Plus Naltrexone Contingency (Type: EXPERIMENTAL): Participants could work and earn vouchers and had to take Vivitrol Injections to work and earn vouchers: employment-based reinforcement.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple sclerosis as diagnosed by the revised 2010 McDonald criteria~* EDSS score between 0 and 5.0 at baseline~Exclusion Criteria:~• Primary progressive multiple sclerosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Interferon beta-1a (Type: ACTIVE_COMPARATOR): Participants received 30 µg interferon beta-1a by intramuscular (IM) injection weekly and matching placebo capsules (identical in physical appearance to ozanimod) orally once a day until the last participant had been treated for 12 months.
- Ozanimod 0.5 mg (Type: EXPERIMENTAL): Participants received ozanimod 0.5 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.
- Ozanimod 1 mg (Type: EXPERIMENTAL): Participants received ozanimod 1 mg capsules orally once a day and an intramuscular placebo injection (identical in appearance to Interferon) weekly until the last participant had been treated for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 18 to 55 years~* Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments.~* If of child bearing potential (both men and women) must agree to use 2 forms of contraceptive methods for the duration of study.~Exclusion Criteria:~* Clinical laboratory values greater than or equal to 2 times the upper limit of normal.~* Recent history (within 2 yrs) or current tobacco use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo intravenous infusion over 30 minutes, five days of once daily dosing
- NP10679 25 mg (Type: EXPERIMENTAL): NP10679 25 mg intravenous infusion over 30 minutes, five days of once daily dosing
- NP10679 50 mg (Type: EXPERIMENTAL): NP10679 50 mg intravenous infusion over 30 minutes, five days of once daily dosing
- NP10679 100 mg (Type: EXPERIMENTAL): NP10679 100 mg intravenous infusion over 30 minutes, five days of once daily dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete